

**SUPPORTING INFORMATION : APPENDIX 1**

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Anna, Goyard, et al.

**High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris**

François Anna<sup>1\*</sup>, Sophie Goyard<sup>2,3\*</sup>, Ana Ines Lalanne<sup>4,5\*</sup>, Fabien Nevo<sup>1,6</sup>, Marion Gransagne<sup>7</sup>, Philippe Souque<sup>6</sup>, Delphine Louis<sup>4,5</sup>, Véronique Gillon<sup>8</sup>, Isabelle Turbiez<sup>8</sup>, François-Clement Bidard<sup>5,9,10</sup>, Aline Gobillion<sup>11</sup>, Alexia Savignoni<sup>11</sup>, Maude Guillot-Delost<sup>5,12</sup>, François Dejardin<sup>13</sup>, Evelyne Dufour<sup>13</sup>, Stéphane Petres<sup>13</sup>, Odile Richard-Le Goff<sup>14</sup>, Zaineb Choucha<sup>7</sup>, Olivier Helynck<sup>15</sup>, Yves L. Janin<sup>15</sup>, Nicolas Escriou<sup>7</sup>, Pierre Charneau<sup>1,6</sup>, Franck Perez<sup>16</sup>, Thierry Rose<sup>2,3\*\*\*</sup>, Olivier Lantz<sup>4,5,12\*\*</sup>

**Author affiliations**

1. Theravectys, Paris, 75015, France
2. Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, 75015, France
3. INSERM 1221, Institut Pasteur, Paris, 75015, France
4. Laboratoire d'Immunologie Clinique, Institut Curie, Paris, 75005, France.
5. Centre d'Investigation Clinique en Biothérapie, Institut Curie (CIC-BT1428), Paris, 75005, France
6. Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, 75015, France
7. Innovation Laboratory: Vaccines, Institut Pasteur, Paris, 75015, France
8. Direction of the Clinical Research, Institut Curie, Paris, 75005, France.
9. Medical Oncology Department, Institut Curie, Paris, 75005, France
10. UVSQ, Paris-Saclay University, Saint-Cloud, 92210, France
11. Biometry, Institut Curie, Paris, 75005, France
12. INSERM U932, PSL University, Institut Curie, Paris, 75005, France
13. Production and purification of recombinant proteins technological platform, Paris, 75015, France
14. Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, 75015, France
15. Unit of Chemistry and Biocatalysis, Institut Pasteur, UMR 3523 CNRS, Paris, 75015, France
16. Unit of Cell Biology and Cancer, Institut Curie, Paris, 75005, France

## **Table of Contents**

### **Supplementary Methods**

- Ethical considerations
- Participant enrolment
- Questionnaire
- Luciferase-Linked Immuno Sorbent Assays (LuLISA)
  - Plasmid design and production of Nucleoprotein and Spike from SARS-CoV-2
  - Plasmid design and production of Nucleoprotein from SARS-CoV-1 and HCoV
  - Design and synthesis of plasmid encoding the anti-IgG nanobody-luciferase tandem
  - Expression, purification and validation of anti-IgG nanobody-Luciferase tandem
  - IgG LuLISA assay protocol
- S-Pseudo-typed Neutralization Assay (PNT)
  - Pseudo-virus production and permissive cell line generation
  - Pseudo-neutralization assay protocol
- Statistical analysis

### **Supplementary Figures**

- Figure S1. Description of anti-IgG VHH Fc1-KAZ and of SARS-CoV2 viral protein targets Nucleoprotein and Spike
- Figure S2. Luciferase-linked immuno-sorbent assay
- Figure S3. Pseudo-neutralization assay (PNT)
- Figure S4. Specificity of assayed IgG against Nucleoproteins of SARS-CoV2 vs SARS-CoV1 and seasonal virus HCoV
- Figure S5. Sequence comparison of SARS-CoV2, SARS-CoV1 and seasonal virus Nucleoproteins
- Figure S6. Serological profile comparison between asymptomatic and symptomatic workers
- Figure S7: PNT raw data for cohort analysis

### **References**

## SUPPLEMENTARY METHODS

### Ethical considerations

This study was registered and received ethical approval by the Comité de Protection des Personnes Méditerranée III (2020.04.18 bis\_ 20.04.16.49458, 27/4/2020) registered in the clinical trial database (NCT04369066). All participants were informed of the study outcomes. All blood samples have been drawn and anonymized at the Institut Curie and their analysis have been performed at the Institut Pasteur, Paris.

### Participant enrolment

The study called volunteer participants working at one of the three Institut Curie locations (Paris, Orsay or Saint Cloud) for four longitudinal blood tests at  $t_0$  then after 1, 3 and 6 months. Following informed consent, 18 years of age or older participant outside of any SARS-CoV-2 acute infectious episode in the last 7 days, completed a web-based questionnaire (Ennov Clinical). Participants covered hospital and non-hospital related activities, age and sex. A 5 mL blood sample was taken from all participants in dry tubes. After clotting, blood was centrifuged 10 min at 2000 g and frozen. Supernatant serum was separated and frozen.

### Questionnaire

The questionnaire provided in Supplementary Appendix 2 recorded individual information and details related to SARS-CoV-2 infection, including date of testing, date of symptom onset and a description of symptoms if there were some. Recorded symptoms were fever, fatigue, cough, difficulty breathing, shortness of breath, loss of taste (ageusia) or smell (anosmia), headache, muscle aches, conjunctivitis or colds, digestive disorders (vomiting, diarrhea).

### Luciferase-Linked Immuno Sorbent Assays (LuLISA)

#### *Plasmid design and production of Nucleoprotein and Spike from SARS-CoV-2*

Production of the Nucleoprotein (N): A codon-optimized gene was synthesized (GeneArt, Thermo Fisher Scientific, Waltham, MA) and subcloned in the pETM11 expression vector<sup>1</sup> allowing the expression of the full-length N protein (UniProtKB ID: P0DTC9) with an amino-end (His)<sub>6</sub> tag in the *E. coli* BL21 (DE3) pDIA17 strain. Bacteria were grown in Nzytech auto-inducible-medium (Lisboa, Portugal) for 4 hours at 37°C then 15 hours at 18°C. Cultures are then centrifuged and the pellets were lysed using a cell disrupter (Constant system Ltd, Daventry Northants, UK) in a phosphate saline lysis buffer (phosphate 50 mM, NaCl 300 mM, pH=8) supplemented with 20 mM imidazole, one complete EDTA-free protease tablet (Merck, Darmstadt, Germany) and 1250 units of benzonase (Merck, Darmstadt, Germany). 2.5mg of RNase was added (Thermo Fisher Scientific, Waltham, MA) and the lysate was further incubated at room temperature for about 20 min. The lysate was centrifuged at 19000 rpm and the soluble fraction was recovered for affinity purification on Protino Ni-NTA 5 ml column (Macherey Nagel, Dueren, Deutschland). The protein was eluted by a 20 - 250 mM imidazole gradient in lysis buffer. The fractions containing the protein of interest were pooled and injected in a Superdex 200 16/600 size-exclusion chromatography column (Cytiva, Velizy, France) equilibrated in a phosphate 50 mM, NaCl 500 mM pH=8 buffer. The protein was eluted as a homodimer and analyzed in denaturing condition on a stain-free SDS PAGE (4–15% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Bio-Rad) as shown in Supplementary Appendix 1 Figure S1 and native condition using multi-angle diffusion light scattering (not shown, Wyatt, CA, USA) for quality validation (Molecular Biophysics Facility, Institut Pasteur). Samples were aliquoted (0.35 mg/mL) and stored at 4°C until use.

**Production of the Spike protein (S):** A codon-optimized nucleotide fragment encoding the ectodomain (amino acid 1 to 1211) of the S protein (UniProtKB ID: P0DTC2) was synthesized (GeneArt, Thermo Fisher), fused to nucleotide fragments encoding the trimerization foldon domain of the bacteriophage T4 fibritin and a Twin-Strep-tag (IBA Life Science, Goettingen, Germany) and subcloned into the pCI vector (Promega, Madison, WI USA). The ectodomain was further stabilized in its uncleaved prefusion state through inactivation of its furine cleavage site (R682G, R683S and R685G) and insertion of the 2 proline mutations (K986P and V987P) described by Kirchdoerfer et al. for SARS-CoV-1 spike protein<sup>2</sup>, respectively. The T4 fibritin foldon ( $\text{g}^1\text{yipeaprdgqA}^{12}\text{YVRKDGEWVLL}^{23}\text{stfl}$ )<sup>3</sup> is used here as an artificial trimerization domain ( $\beta$ -hairpin propeller) for mimicking the Spike trimeric assembly at the virion surface. Expi 293F cells (Life Technologies, Courtaboeuf France) were grown in freestyle 293 expression medium and transfected with the expression vector (300  $\mu\text{g}$  DNA/ 30 mL of freestyle 293 medium) and 300  $\mu\text{l}$  of PEI pro (Polyplus transfection, Illkirch, France). Cells were grown 5 days at 37°C and 8% CO<sub>2</sub>, orbitaly agitated at 110 rpm. The cultures were centrifuged and the supernatant was equilibrated at pH=8.0 with TRIS 1M then concentrated using a 100 kDa MWCO tangential flow filtration cartridge on an Äkta Flux (Cytiva, Velizy France) with a phosphate filtration buffer (phosphate 50 mM, NaCl 300 mM pH=8.0). The retentate was recovered for Twin-Strep-tag-affinity purification on StrepTrap column (Cytiva, Velizy France). The protein was eluted using 2.5 mM desthiobiotine in filtration buffer. The protein was recovered as an homotrimer and analyzed in denaturing condition on a stain-free SDS PAGE (4–15% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Bio-Rad) as shown in Supplementary Appendix 1 Figure S1 and native condition using analytical size exclusion chromatography and multi-angle diffusion light scattering for quality validation (not shown, Molecular Biophysics Platform, Institut Pasteur). Samples were aliquoted (0.52 mg/mL) and stored at 4°C until use.

**Production of Nucleoproteins from SARS-CoV-1 and HCoV:** The optimized synthetic gene (GeneArt, Thermo Fisher) of SARS-CoV1, HCoV-HKU, HCoV-OC43, HCoV-NL63, HCoV-229E (UniProtKB ID: P59595, Q5MQC6, P33469, Q6Q1R8, P15130 respectively) with carboxy-end His<sub>6</sub>-tag and flanking region corresponding to the pET23 sequence (Novagen). pET23 plasmids were amplified with the forward and reverse oligonucleotides using a Q5 DNA polymerase, dNTP mix (New England BioLabs). The PCR products were purified by electrophoresis on agarose gel (1%, Macherey Nagel). The purified pET23 vector and the synthetic genes were assembled using NEBuilder HiFi assembly master mix (New England BioLabs). These plasmid were used to transform *E.coli* BL21 (DE3). Cells were grown at 18°C and induced with IPTG (Sigma-Aldrich). After harvesting the cells by centrifugation (1.5 L), the pellet was resuspended in 50 mM Tris-HCl pH 8.0, 50 mM NaCl with protease inhibitor (Sigma-Aldrich) and lysozyme (0.1 mg/mL, QBIO-gene). Cells were disrupted by freezing-thawing cycle lysis method. DNase (Sigma-Aldrich) was then added to remove DNA from the sample. SARS-CoV-1 and HCoV Nucleoproteins were purified as described for Fc1-nanoKAZ below. The protein quality was analyzed in denaturing condition on a stain-free SDS PAGE (4–15% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Bio-Rad) as shown in Supplementary Appendix 1 Figure S4 and in native condition by acquisition of UV-spectra (240-300 nm). Concentrations were estimated from the solution absorption at 280 nm and sequence by the method of Gill and von Hippel<sup>4</sup>.

#### ***Design and synthesis of plasmid encoding the anti-IgG nanobody-luciferase tandem***

NanoKAZ (19 kDa) is an optimized sequence of the catalytic domain of the luciferase from the subtropical sea shrimp *Oplophorus gracilirostris*<sup>5,6</sup>. The gene *kaz* has been optimized and synthetized by Eurofins (Germany) with carboxy-end His<sub>6</sub>-tag and flanking region corresponding to the pET23 sequence (Novagen). pET23 plasmids were amplified with the forward and reverse oligonucleotides using a Q5 DNA polymerase, dNTP mix (New England BioLabs). The PCR products were purified by

electrophoresis on agarose gel (1%, Macherey Nagel). The purified pET23 vector and the synthetic gene were assembled (pET23-kaz) using NEBuilder HiFi assembly master mix (New England BioLabs).

The Fc IgG-binding moiety ( $K_d=2.14$  nM) is from an antibody of the camelid species alpaca (*Vicugna pacos*) selected against the Fc domain of human IgG (single-domain antibody,<sup>7</sup>). The gene *fc1* has been synthetized by Eurofins with a flanking region corresponding to the pET23-kaz sequence. Synthetic gene *fc1* was amplified with the corresponding forward and reverse oligonucleotides using a Q5 DNA polymerase and dNTP mix. PCR products were purified by electrophoresis on agarose gel. Purified pET23-kaz vector and the synthetic gene *fc1* were assembled using the NEBuilder HiFi assembly master mix. The assembled products (5  $\mu$ L) were used to transform NEB 5-alpha competent *E. coli* and grown overnight on LB/Agar/ampicillin in a Petri dish. Isolated colonies were grown in liquid medium, plasmids were isolated. The full sequence of the anti-IgG nanobody luciferase tandem ([Fc1]-[nanoKAZ]-[His<sub>6</sub>]) was analyzed to confirm the presence of the *fc1*-kaz insert shown in Supplementary Appendix 1 Figure S1.

#### ***Expression, purification and validation of anti-IgG nanobody-Luciferase tandem***

The pET23-fc1-nanokaz was used to transform *E.coli* BL21 (DE3) to achieve high expression in *E.coli*. Cells were grown at 18°C and IPTG (Sigma-Aldrich) was added to induce *fc1-nanoKAZ* production. After harvesting the cells by centrifugation (1.5 L), the pellet was resuspended in 50 mM Tris-HCl pH 8.0, 50 mM NaCl with protease inhibitor (Sigma-Aldrich) and lysozyme (0.1 mg/mL). Cells were disrupted by freezing-thawing cycle lysis method. DNase (Sigma-Aldrich) was then added to remove DNA from the sample.

The crude extract was centrifuged 30 min at 15,000 g. The supernatant was collected and NaCl (500 mM), Imidazole (20 mM, Sigma-Aldrich) and Triton (0.1%, Sigma-Aldrich) were added. The cleared lysate was loaded on a Hi-Trap 5 mL-column (Cytiva, Velizy France) at 4 mL/min using an Äkta pure chromatography system (Cytiva, Velizy France). The column was washed with 20 volumes of column with a running buffer (50 mM Tris-HCl pH 8.0, NaCl 50 mM, 20 mM imidazole) at 5 mL/min. The VHH Fc1-nanoKAZ was eluted with a gradient of imidazole from 20 mM to 200 mM in 50 mM Tris-HCl pH 8.0, 50 mM NaCl at 5 mL/min and fractions of 1 mL were collected in a 96-deepwell plate (Cytiva, Velizy France). Catalytic activity of fractions was profiled using a luminometer Hydex by diluting 10<sup>7</sup> fold the fractions in PBS with 27  $\mu$ M of the imidazo[1,2-*a*]pyrazin-3(7H)-one derivative Q-108 resulting from the hydrolysis of hikarazin-108<sup>8</sup>. The fractions of high activity were pooled, and loaded on a 1 mL HiTrap Q column (Cytiva, Velizy France) equilibrated in 50 mM Tris-HCl pH 8.0, NaCl 50 mM. The protein was eluted in 50 mM MES pH 6.5, 50 mM NaCl at 1 mL/min at 18°C using the Äkta pure chromatography system. The fractions of 500  $\mu$ L were collected in 96-deepwell plates and their activities were assayed as described above. The fractions with high activity were pooled. The quality of the purified protein was assessed by loading an aliquot (10  $\mu$ L) on a stain-free SDS gel (4–15% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Bio-Rad). The gel was activated by UV trans-illumination for 5 min (Bio-Gel Doc XR Imaging System, Bio-Rad). Tryptophan residues undergo an UV-induced reaction with trihalo compounds and produce an imaged fluorescence signal (Supplementary Appendix 1 Figure S1). An UV-spectrum (240-300 nm) was acquired for evaluating the concentration of Fc1-nanoKAZ (MW 34,726 Da) from the solution absorption at 280 nm ( $\epsilon = 50,780$  M<sup>-1</sup>cm<sup>-1</sup> estimated by the method of Gill and von Hippel<sup>4</sup>). The specific activity is about  $4 \cdot 10^{17} \pm 0.5 \cdot 10^{17}$  RLU·s<sup>-1</sup>·g<sup>-1</sup> of Fc1-nanoKAZ.

#### ***IgG LuLISA protocol***

The LuLISA (Luciferase-Linked Immuno-Sorbent Assay) is an ELISA-based method (Enzyme-Linked Immuno-Sorbent Assay) for which the enzyme coupled to the antibody fragment is a luciferase<sup>9</sup> and

is distinguished by the nature of the measurement, the relative number of photons collected per second, which quantifies an instantaneous rate of catalytic reaction, whereas ELISAs measure an accumulation of a product or the disappearance of a substrate, whether absorbent or fluorescent, and whose reaction can be stopped at any time. If the relative number of photons in the first minutes is proportional to the number of luciferases in solution, the measurement must be carefully calibrated with robust references under the same conditions in the same multi-well plates. Indeed, luciferases catalyze the decarboxylation of a luciferin, here Q108 (made by the deacetylation of hikarazine-108)<sup>10</sup>, into an amide in the presence of molecular oxygen with a reaction speed dependant on temperature, amount of dissolved oxygen and substrate concentration. The luciferase used is a nanoKAZ<sup>6</sup> which exhibits inhibition by excess substrate in excess of 54 μM and stochastic inactivation by one of the transient reaction products. The enzyme at the optimum substrate concentration has a half-life of 60 minutes with Q108<sup>8,10</sup>. The antibody fragment is derived from an alpaca heavy single chain (VHH) with an affinity of 0.58, 1.73, 47.8, 0.30 nM (KD) for the Fc domains of human IgG1, IgG2, IgG3 and IgG4 respectively with an average for overall IgG of 2.14 nM<sup>7</sup>. The anti-IgG VHH-nanoKAZ construction is described in Supplementary Appendix 1 Figure S1A.

As shown in the Supplementary Appendix 1 Figure S2, correlation for four replicates of 96 LuLISA IgG/N on a single 384-well plate with fresh sera is greater than 0.97 ( $R^2$ ), roughly pipetting errors aggravated by viscosity and protein aggregation variations.  $R^2$  is 0.96 on four different plates, 0.88 to 0.92 between frozen and fresh sera loaded on the same plate and 0.82 to 0.88 when loaded on different plates one month apart while it is 0.88 to 0.96 when loaded with frozen sera at the same time on different plates, 0.92 to 0.96 on the same plates. Both the LuLISA and ELISA are sensitive to the storage quality of the sera, in particular to the thawing conditions which contribute to the denaturation of proteins, in particular albumin, and which cause the formation of aggregates that can pull down immunoglobulins and alter the concentration of soluble specific Ig.

White 384-well plates with flat bottoms (Fluorounic C384 Maxisorp, Nunc) were coated with either 1 μg/mL of Nucleoprotein or Spike protein in PBS buffer, 50 μL/well for 3 hours at room temperature or overnight at 4°C. Wells were washed using a plate washer (Zoom, Berthold Technologies, Germany) two cycles of three times with 100 μL of PBS/Tween 20 0.1%. Sera were diluted 200 times in PBS, non-fat milk 3% and Tween 20 0.1%. 50μL of serum dilutions were incubated 1 hour at room temperature in their respective wells. Wells were washed two cycles of three times with 100 μL of PBS/Tween 20 0.1%. Purified Fc1-nanoKAZ 1 ng/mL ( $400 \cdot 10^6 \text{ RLU} \cdot \text{s}^{-1} \cdot \text{mL}^{-1}$ ) in PBS, non-fat milk 3% and Tween 20 0.1% was loaded (50 μL/well) and incubated 30 min at room temperature. Wells were washed two cycles of three times with 100 μL of PBS/Tween 20 0.1%. Plates can be stored at this step in PBS until measurements. Just before reading, each of the wells were emptied and loaded with 50 μL of Q-108 at 13 μM. The plate was orbitaly shaken for 3 seconds and the collected photons were counted during 1 sec per well and measured 3 times in a plate luminometer (Mithras2, Berthold, Wildbad, Germany).

#### **S-Pseudo-typed neutralization assay**

#### **Pseudo-virus production and permissive cell line generation**

Pseudo-typed vectors were produced and titrated as previously described<sup>11</sup>. Adaptation of the protocol are : cells were co-transfected with calcium-phosphate precipitation protocol with 10 μg of packaging plasmid encoding for gag-pol-tat-rev proteins (p8.74), 10μg of vector plasmid (pTrip-CMV) expressing luciferase Firefly reporter and 5 μg of envelop plasmid expressing a codon-optimized full-length S SARS-CoV-2 (UniProtKB ID: PODTC2) sequence amplified by PCR from pMK-RQ\_S-2019-nCoV with adaptative primers and introduced by BamHI/Xhol restriction/ligation in a pCMV plasmid. Pseudo-typed vectors were harvested at day 2 post-transfection. Functional titer (TU) was determined by SYBRgreen qPCR after transduction of a stable HEK 293T-hACE2 cell line using two couples of primers to either quantify vector genome (forward CMV: ACT GCC AAA ACC GCA TCA CC reverse CMV: AAT

GAC GGT AAA TGG CCC GC) or cell genome (forward GADPH: TCT CCT CTG ACT TCA ACA GC reverse GADPH: CCC TGC ACT TTT TAA GAG CC). To generate the permissive cell line, HEK 293T cells were transduced at MOI 20 with an integrative lentiviral vector expressing cDNA human ACE2 (UniProtKB ID: Q9BYF1) codon-optimized gene (Eurofins) under the control of UBC promoter. Clones were generated by limiting dilution and selected for their permissivity to SARS-CoV-2 S pseudo-typed lentiviral vector transduction with a Luciferase Assay System (Promega).

#### **Pseudo-neutralization assay protocol**

First, sera were decomplemented at 56°C during 30 min in a water bath. To determine EC<sub>50</sub> serum dilutions (from 1/40 to 1/40960 by successive 4-fold dilutions) are mixed and co-incubated with 300 TU of pseudo-typed vector at room temperature during 30 minutes under agitation. Both, serum and vector are diluted in culture medium DMEM-glutamax (Gibco) + 10% FCS (Gibco) + Pen/Strep (Gibco). Mix is then plated in tissue culture treated black 96-well plate clear bottom (Costar) with 20 000 HEK 293T-hACE2 cells in suspension. To prepare the cell suspension, the cell flask is washed with DPBS twice (Gibco) and cells are individualized with DPBS + 0.1% EDTA (Sigma-Aldrich) to preserve hACE2 protein. After 48h incubation at 37°C 5% CO<sub>2</sub>, the medium is completely removed by aspiration and bioluminescence is measured using a Luciferase Assay System (Promega) on an EnSpire plate reader (PerkinElmer).

#### **Statistical analyses**

Seropositivity was defined as the presence of detectable anti-SARS-CoV-2 antibodies against N or S. The proportion of seropositive samples was compared by time between onset of symptoms and collection of blood sample using chi-square test.

LuLISA, and pseudo-neutralization of sera were compared by delay since onset of symptoms using the Kruskall-Wallis non-parametric test. The chi-square test was used to evaluate the association between investigated factors and neutralization levels.

All analyses were performed using GraphPad Prism 8 (GraphPad Software, LLC).


#### **References**

1. Dummler A, Lawrence AM, de Marco A. Simplified screening for the detection of soluble fusion constructs expressed in *E. coli* using a modular set of vectors. *Microb Cell Fact* 2005;4:34.
2. Kirchdoerfer RN, Wang N, Pallesen J, et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. *Sci Rep* 2018;8:15701.
3. Meier S, Guthe S, Kiehaber T, Grzesiek S. Foldon, the natural trimerization domain of T4 fibrin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. *J Mol Biol* 2004;344:1051-69.
4. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. *Anal Biochem* 1989;182:319-26.
5. Hall MP, Unch J, Binkowski BF, et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. *ACS Chem Biol* 2012;7:1848-57.
6. Inouye S, Sato J, Sahara-Miura Y, Yoshida S, Hosoya T. Luminescence enhancement of the catalytic 19 kDa protein (KAZ) of Oplophorus luciferase by three amino acid substitutions. *Biochem Biophys Res Commun* 2014;445:157-62.
7. Hermans WJJ, Bezemer S, Mijnsbergen YM, inventors; Single-domain antigen-binding proteins that bind mammalian IgG patent WO 2009/011572 Al. 2009 8 July 2008 (08.07.2008).

8. Coutant EP, Goyard S, Hervin V, et al. Gram-scale synthesis of luciferins derived from coelenterazine and original insights into their bioluminescence properties. *Org Biomol Chem* 2019;17:3709-13.
9. Goyard S, Balbino B, Chinthrajah RS, et al. A highly sensitive bioluminescent method for measuring allergen-specific IgE in microliter samples. *Allergy* 2020.
10. Coutant EP, Gagnot G, Hervin V, et al. Bioluminescence Profiling of NanoKAZ/NanoLuc Luciferase Using a Chemical Library of Coelenterazine Analogue. *Chemistry* 2020;26:948-58.
11. Iglesias MC, Mollier K, Beignon AS, et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. *Mol Ther* 2007;15:1203-10.

A

- Anti-IgG VHH Fc1-KAZ



- SARS-CoV-2 Nucleocapsid (N) full length




- SARS-CoV-2 Spike (S) stabilized ecto domain



B


C

D




## Figure S1 Description of anti-IgG VH<sub>1</sub>-Fc1-KAZ and of SARS-CoV2 viral protein targets nucleoprotein and spike.

**(A)** Scheme of protein topology used in the study. Quality control of proteins used as targets on SDS-polyacrylamide gel electrophoresis. Proteins were run on a 4-15% gradient gel and visualized by UV-induced fluorescence of tryptophan-bound trihalo compounds (**B**) or by western blot analysis after transfer onto the PVDF proteins using stain-free system (Bio-Rad) (**C**) or luminescence (**D**). Lane 1: Purified VHH-anti IgG Fc1-nanoKaz (2 µg); Lane 2, purified protein SARS-CoV Spike (6 µg); Lane 3 Nucleoprotein (3 µg). Molecular weights are indicated by arrows.

**Figure S2 Luciferase-linked immuno-sorbent assay**


(A) Scheme of the LuLISA assay. (B) LuLISA of titration of N-specific IgG from patients' sera (Hospital Cochin). Serial dilutions of sera from  $10^{-1}$  to  $10^{-8}$  in PBS. (C) Four repeats of IgG/N LuLISA on the same series of 96 diluted sera in PBS (1/200). (D) Comparison of the 4 IgG/N LuLISA vs IgG/N ELISA (HRP-anti-human IgG) showing the large dynamic scale of LuLISA vs ELISA. (E) The grey zone in D is zoomed showing the higher sensibility of LuLISA (low dispersion of LuLISA values, high dispersion of ELISA values below DO 1.2 for dilution 1/200) and the loss of linearity beyond absorbance 1.2. Threshold 98%, DO 1.2, 10400 RLU/s are indicated with dashed lines.

**A**




**B**


- Envelope Plasmids :




- Packaging Plasmid :




- Plasmid vectors : Backbone pTrip




**C**




**D**




**E**



**F**



**G**



**Figure S3: Pseudo-neutralisation assay (PNT)**

**(A) Schematic representation of Pseudo-neutralization assay.**

**(B) Production plasmids used to generate lentiviral vectors.**


ieCMV: human Immediate early Cytomegalovirus promoter. WPRE : Woodchuck Post-translational Regulatory Element. VSV-G Glycoprotein from Vesicular Stomatitis Virus (serotype Indiana). Gag-Pol-Tat-rev proteins from HIV-1 Strain NDK. BGH Poly A : Polyadenylation Site from Bovine Growth Hormone gene. All following fragments come from HIV-1 Strain NL4.3 : U3RU5 : Full length Long Terminal Repeat,  $\phi$  : Encapsidation sequence, RRE: Rev Response Element, RU5 : Truncated Long Terminal Repeat. hUBC : human Ubiquitine C promoter.

**(C) Control of hACE2 expression in 293T::hACE2 reporter cell line by FACS.** To verify the expression and membrane location of hACE2 protein, parental cell line (293T WT) and hACE2 expressing clone (293T::hACE2) were first labelled polyclonal antibodies anti-hACE2 (AF933, R&D) then a PE-coupled secondary antibody (A32849, Invitrogen). Samples were acquired on a Attune FACS (ThermoFisher).

**(D) Control of 293T::hACE2 permissivity et specificity to S-pseudotyped lentiviral vector transduction.** Parental cell line and hACE2 clone were transduced with S-pseudotyped lentiviral vector (or VSV-G, an amphotropic envelope as control). To assess that signal is specific to vector particles, equivalent heat-inactivated samples ( $70^{\circ}\text{C}$  30min in a water bath) were also tested.


**(E) Threshold determination on different serum collections.** To setup up the experimentation, Min-max values are determined on untransduced cells and prepanademic serum (dilution 1/40) respectively, Covid-19 patients are used as positive controls. To define positiveness threshold with a confidence index >99%, this value is set at Mean (prepanademic) – 3 Standard deviation. During sample analysis, all samples are firstly evaluated for positiveness at dilution 1/40. If the value is below threshold, then ID50 is determined as described below in a second experiment.

**F-G Dilution curves and ID50 determination.** First, raw data (grey points) **(F)** are transformed into percentage of neutralization **(G)**. This percentage is determined according to mean of prepanademic serums (0%) and untransduced cells (100%) values. Second, a non-linear regression is performed (plotted line in graph G) to determine the theoretical dilution that give a 50% inhibition (ID50). A prepanademic sample (Black point) is shown as negative example. Detection limit was set at 40 considering the maximum reached value by prepanademic samples.



**Figure S4 Specificity of assayed IgG against nucleoprotein of SARS-CoV2 vs SARS-CoV1 and seasonal virus HCoV:** (A) Protein constructs with His Tag (LEHHHHHH). (B) Control of expressed and purified proteins used as targets using SDS-polyacrylamide gel electrophoresis. The gel is an acrylamide gradient from 4 to 15%. Lane 1: purified protein Nucleocapsid from HCoV-HKU, HCoV-OC43, HCoV-NL63, HCoV-229E and SARS-CoV1 (stain free system, BioRad). (C) IgG/S vs IgG/N SARS-CoV2 from Curie series ( $n=376$ ). (D) IgG LuLISA against N SARS-CoV1 vs SARS-CoV2 (**E**) IgG LuLISA against N HCoV vs SARS-CoV2 from Curie series ( $n=376$ ). (F) IgG LuLISA against N SARS-CoV2, SARS-CoV1, HCoV-OC43, HCoV-NL63, HCoV-229E, HCoV-HKU.


## Anna et al. Supplementary Appendix 1 Figure S5



**Figure S5 Sequence comparison of SARS-CoV2, SARS-CoV1 and seasonal virus nucleoproteins**


Multiple sequence alignments of the four human seasonal coronavirus (HCoV) and the SARS-CoV Nucleoproteins. The alignment was performed using Clustal Omega software from <http://www.ebi.ac.uk/Tools/msa/clustalo>.

Grey background indicates conserved residues in at least 4 sequences. Conserved residues within the two alphacoronavirus and the two beta-coronavirus are highlighted in yellow and blue, respectively with SarS-CoV when applicable. Residues in red denote aromatic residues potentially involved in base stacking interactions when binding to RNA. Red dashed boxes enlight conserved patterns.



**Figure S6: Serological profile comparison between asymptomatic and symptomatic workers**

Institut Curie workers were separated in asymptomatic and symptomatic groups according to survey answers. Symptomatic workers reported at least one symptom (listed in table II). Global seroprevalence in LuLISA IgG/N (A), LuLISA IgG/S (B), PNT (C) are shown as raw values. Proportion of seropositive workers is indicated in bold. Proportion of asymptomatic and symptomatic among seropositive workers in LuLISA IgG/N (D), LuLISA IgG/S (E), PNT (F) are represented by whisker-plots. Proportion among total seropositive workers is indicated below in bold. Statistical significance was determined using a Mann-Whitney test (\*:p<0.05; ns: non significant).



**Figure S7: PNT raw data for cohorts analysis**

Serum dilution factor:1/40. Positive samples are below the threshold level. Threshold is calculated on raw values of prepandemic sera from a blood bank (see Figure S3). ID50 was determined on positive samples (see Figure 1 and Figure S3)

**SUPPORTING INFORMATION : APPENDIX 2**

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Anna, Goyard, et al.

**High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris**

François Anna<sup>1\*</sup>, Sophie Goyard<sup>2,3\*</sup>, Ana Ines Lalanne<sup>4,5\*</sup>, Fabien Nevo<sup>1,6</sup>, Marion Gransagne<sup>7</sup>, Philippe Souque<sup>6</sup>, Delphine Louis<sup>4,5</sup>, Véronique Gillon<sup>8</sup>, Isabelle Turbiez<sup>8</sup>, François-Clement Bidard<sup>5,9,10</sup>, Aline Gobillion<sup>11</sup>, Alexia Savignoni<sup>11</sup>, Maude Guillot-Delost<sup>5,12</sup>, François Dejardin<sup>13</sup>, Evelyne Dufour<sup>13</sup>, Stéphane Petres<sup>13</sup>, Odile Richard-Le Goff<sup>14</sup>, Zaineb Choucha<sup>7</sup>, Olivier Helynck<sup>15</sup>, Yves L. Janin<sup>15</sup>, Nicolas Escriou<sup>7</sup>, Pierre Charneau<sup>1,6</sup>, Franck Perez<sup>16</sup>, Thierry Rose<sup>2,3\*\*\*</sup>, Olivier Lantz<sup>4,5,12\*\*</sup>

**Author affiliations**

1. Theravectys, Paris, France
2. Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, 75015, France
3. INSERM 1221, Institut Pasteur, Paris, 75015, France
4. Laboratoire d'Immunologie Clinique, Institut Curie, Paris, 75005, France.
5. Centre d'Investigation Clinique en Biothérapie, Institut Curie (CIC-BT1428), Paris, 75005, France
6. Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, 75015, France
7. Innovation Laboratory: Vaccines, Institut Pasteur, Paris, 75015, France
8. Direction of the Clinical Research, Institut Curie, Paris, 75005, France.
9. Medical Oncology Department, Institut Curie, Paris, 75005, France
10. UVSQ, Paris-Saclay University, Saint-Cloud, 92210, France
11. Biometry, Institut Curie, Paris, 75005, France
12. INSERM U932, PSL University, Institut Curie, Paris, 75005, France
13. Production and purification of recombinant proteins technological platform, Paris, 75015, France
14. Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, 75015, France
15. Unit of Chemistry and Biocatalysis, Institut Pasteur, UMR 3523 CNRS, Paris, 75015, France
16. Unit of Cell Biology and Cancer, Institut Curie, Paris, 75005, France

## **Anna et al, Supplementary Appendix 2**

This questionnaire was submitted with the description of the study for ethical approval by the Comité de Protection des Personnes Méditerranée III (2020.04.18 bis\_ 20.04.16.49458, 27/4/2020) registered in the clinical trial database (NCT04369066). The items of this questionnaire were recorded in the Curiosa Web-based survey.

### **Questionnaire**

- Working Site (Paris Hospital/Saint Cloud Hospital/Orsay site/Administrative Staff/Research Center)
- Age (years)
- Weight (kg)
- Height (cm)
- Confinement (Yes/No)
- Confinement start (date)
- Working mode at the time of the blood withdrawal (Site /Institute and home-office)
- Symptoms (fever, tiredness, cough, shortness of breath, difficulty breathing, muscle aches, conjunctivitis, rhinitis, anosmia/ageusia, unusual headache, digestive disorders (vomiting, diarrhea))
- Symptom onset (date)
- Symptom end (date)
- PCR\_assay done (yes/no)
- PCR\_assay (date)
- PCR result (Positive/Negative)
- Treatment (hospitalization/systemic treatment)
- Hospitalization (days)
- Intensive care unit (yes/no)

### SUPPORTING INFORMATION : APPENDIX 3

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Anna, Goyard, et al.

### High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris

François Anna<sup>1\*</sup>, Sophie Goyard<sup>2,3\*</sup>, Ana Ines Lalanne<sup>4,5\*</sup>, Fabien Nevo<sup>1,6</sup>, Marion Gransagne<sup>7</sup>, Philippe Souque<sup>6</sup>, Delphine Louis<sup>4,5</sup>, Véronique Gillon<sup>8</sup>, Isabelle Turbiez<sup>8</sup>, François-Clement Bidard<sup>5,9,10</sup>, Aline Gobillion<sup>11</sup>, Alexia Savignoni<sup>11</sup>, Maude Guillot-Delost<sup>5,12</sup>, François Dejardin<sup>13</sup>, Evelyne Dufour<sup>13</sup>, Stéphane Petres<sup>13</sup>, Odile Richard-Le Goff<sup>14</sup>, Zaineb Choucha<sup>7</sup>, Olivier Helynck<sup>15</sup>, Yves L. Janin<sup>15</sup>, Nicolas Escriou<sup>7</sup>, Pierre Charneau<sup>1,6</sup>, Franck Perez<sup>16</sup>, Thierry Rose<sup>2,3\*\*\*</sup>, Olivier Lantz<sup>4,5,12\*\*</sup>

### Author affiliations

1. Theravectys, Paris, France
2. Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, 75015, France
3. INSERM 1221, Institut Pasteur, Paris, 75015, France
4. Laboratoire d'Immunologie Clinique, Institut Curie, Paris, 75005, France.
5. Centre d'Investigation Clinique en Biothérapie, Institut Curie (CIC-BT1428), Paris, 75005, France
6. Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, 75015, France
7. Innovation Laboratory: Vaccines, Institut Pasteur, Paris, 75015, France
8. Direction of the Clinical Research, Institut Curie, Paris, 75005, France.
9. Medical Oncology Department, Institut Curie, Paris, 75005, France
10. UVSQ, Paris-Saclay University, Saint-Cloud, 92210, France
11. Biometry, Institut Curie, Paris, 75005, France
12. INSERM U932, PSL University, Institut Curie, Paris, 75005, France
13. Production and purification of recombinant proteins technological platform, Paris, 75015, France
14. Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, 75015, France
15. Unit of Chemistry and Biocatalysis, Institut Pasteur, UMR 3523 CNRS, Paris, 75015, France
16. Unit of Cell Biology and Cancer, Institut Curie, Paris, 75005, France

### SUPPLEMENTARY APPENDIX 3 to Anna, et al.

High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris

Individuals			LuLISA IgG/N			positive if >13400 RLU/s			Threshold 98% specificity			Symptoms												RT-qPCR		
ID	sex	age	Latreal flow test	LuLISA IgG/N M0	LuLISA IgG/S M0	PNT	M0	seropositivity y M0	LuLISA IgG/N M1	LuLISA IgG/S M1	PNT	M1	seropositivity y M1	any symptom	Fever	Tiredness	Cough	Short breath /difficulty breathi	Muscle ache	Conjunctivitis	Rhinitis	nosmia/ageusia	usual headache	digestive disord	RT-qPCR	RT-qPCR results
1 F	39-82	1471	1384	0	0	5325	1123	0	0	1	0	1	0	0	0	1	0	1	0	1	0	1	0	0	0	0
2 F	19-38	6518	3614	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	1	0	1	1	0	0	0	0
3 F	39-82	3142	2333	0	0	1692	2391	0	0	1	1	1	1	0	0	1	0	0	0	0	1	1	1	1	0	0
4 F	19-38	2978	706	0	0	1322	1132	0	0	1	0	1	0	0	0	0	0	1	1	0	1	1	1	0	0	0
5 F	39-82	3680	2039	0	0	2457	2349	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
6 F	19-38	27456	42832	67	1	25056	64694	85	1	1	1	1	0	1	0	0	1	0	1	0	0	1	1	1	1	1
7 F	19-38	3876	1002	0	0	1830	531	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8 F	39-82	2230	750	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	1	1	1	0	0	1	1	1	0	0
9 F	39-82	4825	834	0	0	2066	728	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10 F	39-82	3386	2326	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	0	0	0	0	0	0	1	1	0	
11 F	19-38	1728	651	0	0	1064	1356	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12 F	19-38	5639	2099	0	0	5485	1939	0	0	1	1	1	1	0	0	1	0	0	0	0	0	1	0	0	0	0
13 F	19-38	4308	1222	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0
14 F	19-38	1762	1341	0	0	1587	834	0	0	1	0	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0
15 F	39-82	2340	1366	0	0	2265	1230	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16 F	19-38	2534	768	0	0	2280	895	0	0	1	0	1	1	0	0	1	0	1	0	1	0	1	1	1	0	0
17 F	19-38	2678	1279	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	1	0	0	0	0	1	1	1	0	
18 F	19-38	3124	1418	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19 F	19-38	19275	13925	8	1	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20 M	39-82	61536	26285	70	1	18885	15880	12	1	1	1	1	1	1	0	0	1	0	0	1	1	1	1	1	1	1
21 F	39-82	3809	3197	0	0	2968	978	0	0	1	0	1	0	1	0	0	1	1	1	0	0	1	0	0	0	0
22 F	39-82	4161	787	0	0	3414	699	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
23 F	39-82	7182	2614	0	0	6889	2012	18	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24 F	39-82	6357	973	0	0	2585	924	12	1	1	0	1	0	1	0	0	0	0	0	0	1	0	1	0	1	0
25 F	39-82	5740	1430	0	0	2166	1557	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
26 F	39-82	2065	797	0	0	1898	1340	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
27 M	19-38	2379	1198	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0
28 F	19-38	2642	2064	0	0	3523	3987	0	0	1	0	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0
29 M	19-38	1442	592	0	0	1081	779	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
30 F	39-82	2727	723	0	0	1662	1250	0	0	1	0	1	1	1	1	0	0	0	0	0	0	0	1	0	0	0
31 F	39-82	8958	1061	0	0	7118	818	0	0	1	1	1	1	1	0	0	0	0	0	1	0	0	0	0	0	0
32 F	19-38	50372	63596	89	1	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	0	1	0	1	0	1	0	1	1	
33 F	39-82	170080	181385	99	1	134053	258571	80	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1
34 F	19-38	1184	1625	0	0	735	1093	0	0	1	0	1	0	1	0	1	0	0	0	0	1	0	1	0	1	0
35 F	19-38	1302	1679	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	1	0	0	0	0	1	0	1	0	0	
36 F	39-82	101108	144045	96	1	91483	88102	98	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0
37 F	39-82	1514	816	0	0	1119	1509	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
38 F	19-38	3639	1207	0	0	3331	537	0	0	1	1	1	1	1	0	0	1	0	1	0	0	0	1	0	0	0
39 F	39-82	4293	757	0	0	2991	1926	33	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
40 F	39-82	2427	861	0	0	1043	1163	0	0	1	0	1	0	1	1	1	0	1	0	1	1	0	0	0	1	0
41 M	19-38	1510	2228	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
42 M	39-82	136689	33141	15	1	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	0	0	0	0	1	1	1	1	1	
43 F	39-82	4467	1388	0	0	2499	750	0	0	1	1	1	1	0	1	1	1	1	0	0	0	1	0	1	0	0
44 M	39-82	2755	797	0	0	#N/A	#N/A	#N/A	#N/A	1	1	0	1	0	1	0	0	0	0	1	1	1	1	0	0	
45 F	19-38	2211	1245	0	0	750	965	0	0	1	0	1	0	1	0	0	0	0	0	0	1	0	0	0	0	0
46 M	19-38	4720	682	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	0	0	0	1	0	0	0	0	0	
47 F	39-82	6642	904	0	0	3097	621	0	0	1	0	1	0	1	0	0	0	1	0	0	1	1	0	0	0	0
48 F	19-38	23523	13803	63	1	7702	118340	30	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0
49 F	39-82	3767	1598	0	0	1910	1157	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
50 M	39-82	317013	185033	97	1	217380	117537	98	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0
51 M	19-38	61199	36432	60	1	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
52 F	19-38	31057	55494	38	1	6482	4301	44	1	1	0	1	1	1	1	1	1	0	0	0	1	1	1	0	1	
53 F	39-82	1501	1468	0	0	501	380	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
54 F	39-82	4240	1047	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
55 F	39-82	2852	5273	0	0	1340	982	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
56 F	19-38	1670	705	0	0	1061	972	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
57 F	39-82	2207	509	0	0	1047	971	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
58 M	19-38	109629	24644	98	1	65895	39420	96	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
59 M	19-38	5750	1215	0	0	4846	2345	0	0	1	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0
60 F	39-82	2944	2498	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
61 M	19-38	1896	1111	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	0	0	0	0	1	0	1	1	1	0	0
62 F	39-82	178273	62571	91	1	132619	47834	70	1	1	1	0	1	0	1	0	1	0	1	1</td						









388 F	19-38	2715	918	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
389 F	39-82	3449	519	0	0	858	509	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
390 F	39-82	5687	508	0	0	2878	1496	0	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0
391 F	39-82	2385	455	0	0	1325	585	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0
392 F	39-82	2852	789	0	0	2317	1961	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
393 F	19-38	5210	1168	0	0	1486	2103	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0
394 F	39-82	3287	825	0	0	2230	1360	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
395 F	19-38	2650	1879	0	0	3313	1696	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
396 F	19-38	2003	681	0	0	3608	1318	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
397 F	39-82	3364	749	0	0	4550	504	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
398 F	19-38	1096	370	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	1	0	0	0	0	0	1	0	0
399 F	19-38	5588	740	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
400 F	19-38	3947	644	0	0	3692	2145	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	1	1	0
401 F	19-38	1080	1071	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	1	0	0	0	0	0	0	1	0
402 F	19-38	1409	708	0	0	2062	1326	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0
403 F	39-82	9100	2285	0	0	6960	1139	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
404 F	19-38	7190	1894	0	0	1999	4323	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
405 F	39-82	1853	1508	0	0	212	233	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
406 F	39-82	9996	1445	0	0	9417	2622	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
407 F	19-38	2380	574	0	0	1754	874	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
408 F	39-82	1155	1228	0	0	1024	1995	10	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0
409 M	19-38	5095	1080	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	1	0	0	0	0	0	1	0	1
410 M	39-82	2987	1308	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	0	0	0	1	0	1	1	1	0	1	0	0
411 F	39-82	1564	797	0	0	1471	3877	0	0	1	0	1	1	1	0	1	1	1	1	1	0	1	0	0	0
412 F	39-82	3300	3510	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
413 F	19-38	negative	1513	1153	0	0	1260	4622	0	0	1	1	1	1	0	0	1	0	0	0	1	0	0	0	0
414 M	39-82	968	394	0	0	1955	473	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
415 F	19-38	1766	494	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	1	1	1	0	1	1	0	0	0
416 F	19-38	3791	765	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	0	0	0	1	0	1	1	0	1	1	0	0
417 F	19-38	2495	866	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	1	0	0	0	0	0	0	1	0	0
418 M	39-82	1897	515	0	0	1663	1338	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
420 M	19-38	3992	831	0	0	2113	1324	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0
421 F	19-38	2699	990	0	0	1317	1669	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
422 F	39-82	negative	2115	1058	0	0	951	1776	0	0	1	1	1	1	1	1	1	0	0	0	1	1	0	1	0
423 M	19-38	3623	988	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
424 F	19-38	2397	768	0	0	2186	1838	0	0	1	0	1	0	1	0	1	0	0	0	0	0	0	1	1	0
425 F	39-82	190967	32660	90	1	122201	62768	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	1	1
426 F	39-82	3343	2811	0	0	4460	3144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
427 F	19-38	7989	1324	0	0	4124	5884	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
428 M	19-38	2407	1550	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	0	0	0	0	0	1	1	0	
429 F	19-38	15939	23150	2	1	10334	64251	89	1	1	0	1	0	0	0	0	0	0	0	0	1	1	0	1	0
430 F	19-38	6359	846	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
431 F	39-82	4034	821	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
432 F	19-38	7428	562	0	0	3507	1082	0	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	0	0
433 F	19-38	2732	884	0	0	732	1056	0	0	1	0	1	0	1	0	1	1	1	0	0	0	1	0	0	0
434 F	19-38	3133	1058	0	0	2422	2741	0	0	1	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0
435 F	19-38	37875	923	0	0	1	47894	1021	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	1	1
436 M	19-38	3811	1055	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
437 F	39-82	1463	341	0	0	535	380	0	0	1	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0
438 M	19-38	3138	1862	0	0	#N/A	#N/A	#N/A	#N/A	1	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0
439 F	19-38	3524	814	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
440 F	19-38	3742	1283	0	0	1597	1285	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0
441 F	39-82	2621	399	0	0	733	701	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
442 F	39-82	4392	1083	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
443 F	39-82	2019	623	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0
444 M	19-38	1643	593	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	1	1	0
445 F	39-82	1726	561	0	0	830	1177	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
446 F	39-82	1504	899	0	0	712	2275	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
447 F	39-82	59688	33687	5	1	27002	20562	3	1	1	0	1	0	1	0	0	0	0	1	0	0	0	0	1	0
448 F	39-82	70690	25703	85	1	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	1	1	0	0	0
449 M	39-82	9532	2928	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0
450 F	39-82	1150	322	0	0	1261	584	0	0	1	1	0	1	0	0	0	0	0	0	0	1	0	0	1	0
451 M	19-38	2513	1505	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0
452 F	39-82	1184	439	0	0	936	702	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
453 M	39-82	1125	770	0	0	1324	480	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
455 M	19-38	1372	472	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
456 M	39-82	2625	2059	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	1	0	0	1	1	0	0	0	0	0
457 M	39-82	2130	699	0	0	954	899	0	0																

467 F	19-38	2465	623	0	0	1505	1094	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
468 F	39-82	3424	1262	0	0	2264	1256	0	0	1	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0
469 M	39-82	1844	883	0	0	832	473	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
470 M	19-38	1540	960	0	0	1920	1244	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0
471 F	19-38	3060	819	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	0	0	0	0	0	0	0	0	1	0	0
472 F	39-82	1874	1260	0	0	2289	1508	0	0	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0
473 F	39-82	1062	247	0	0	1484	1118	0	0	1	0	1	1	0	0	0	1	0	1	0	1	0	1	0	0
474 F	19-38	1651	1403	0	0	1461	1887	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
475 F	39-82	6229	819	0	0	6344	783	0	0	1	0	1	1	0	0	0	0	0	1	1	0	1	1	0	0
476 F	19-38	3072	906	0	0	1687	977	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
477 F	19-38	3771	1008	0	0	4900	1522	0	0	1	1	1	1	0	0	0	0	0	0	1	1	1	1	0	0
478 F	19-38	1765	1870	0	0	1981	2951	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
479 F	19-38	1352	2052	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
480 F	19-38	1359	723	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
481 F	19-38	2167	1486	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0
482 F	39-82	1165	432	0	0	1554	841	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
483 F	19-38	841	390	0	0	1313	807	0	0	1	1	1	1	0	0	1	0	0	0	1	0	1	0	0	0
484 F	19-38	2011	1192	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
485 F	39-82	2060	779	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
486 F	39-82	2011	661	0	0	3462	669	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
487 F	19-38	1722	1325	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0
488 F	19-38	1913	537	0	0	1588	523	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	1	0	1
489 F	39-82	6084	3360	0	0	4059	2109	53	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
490 M	39-82	3380	650	0	0	4753	456	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
491 F	39-82	2604	542	0	0	3450	819	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
492 F	39-82	16358	752	0	1	13879	234	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
493 F	39-82	2512	498	0	0	1497	236	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
494 F	39-82	4545	537	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0
495 M	19-38	2417	717	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	1	0	1	1	1	0	0	0	0
497 F	19-38	2034	599	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	1	1	0	1	1	0	0	0	0
498 M	39-82	1863	698	0	0	1983	1188	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
499 F	19-38	5267	788	0	0	7737	1840	0	0	1	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0
500 F	19-38	IgG/IgM positi	11698	21457	34	1	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1
501 M	19-38	4209	1919	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
502 F	19-38	2013	718	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
503 M	19-38	7909	3017	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
504 F	19-38	4333	952	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
505 F	39-82	7586	1027	0	0	8998	1749	0	0	1	1	1	1	0	0	0	1	0	1	0	0	0	0	1	0
506 M	39-82	2522	512	0	0	1247	2050	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0
507 F	39-82	3502	1157	0	0	1849	1200	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
508 F	39-82	1610	394	0	0	1345	776	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
509 F	39-82	7037	1101	0	0	4045	1479	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
510 M	19-38	4477	757	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0
511 F	39-82	3790	1054	0	0	1123	1247	0	0	1	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
512 F	19-38	3007	1147	0	0	2766	3341	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
513 F	19-38	2129	359	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
514 F	39-82	2365	467	0	0	1325	1698	0	0	1	0	1	0	1	1	1	1	1	1	0	0	0	1	0	0
515 F	39-82	1784	618	0	0	3132	733	2	1	1	0	1	1	1	0	0	0	1	1	1	0	1	1	0	0
516 F	39-82	2435	554	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
517 M	39-82	2941	313	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
518 M	39-82	3265	433	0	0	1919	1880	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
519 F	19-38	8499	1774	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0
520 F	39-82	2753	680	0	0	1617	1048	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
521 F	39-82	4968	1896	0	0	1063	1317	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
522 F	19-38	5696	2655	0	0	3507	2197	0	0	1	1	1	1	1	1	1	1	1	1	0	0	1	1	0	0
523 F	39-82	4909	1216	0	0	3632	1612	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
524 F	19-38	2901	802	0	0	2184	1433	0	0	1	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0
525 M	39-82	4449	5410	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	1	0	0	0	1	1	1	1	0	1	0	0	0
526 M	19-38	27885	59700	91	1	34846	75982	0	1	1	1	1	1	1	1	1	1	1	1	1	0	1	0	0	1
527 M	19-38	1503	688	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
528 F	19-38	3126	880	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
529 F	39-82	5380	553	0	0	4643	1091	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
530 F	39-82	2968	2132	0	0	2960	2850	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
531 F	19-38	3431	2892	0	0	6041	5762	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
532 F	19-38	3508	654	0	0	2059	964	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
534 M	19-38	2835	231	0	0	2440	1021	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
535 M	19-38	1485	474	0	0	1963	845	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0
536 F	39-82	146998	52781	97	1	181153	95																		

547 F	19-38		62242	26170	40	1	#N/A	#N/A	#N/A	#N/A	1	0	0	1	0	0	1	0	1	1	1	1	0	1	0
548 F	19-38		1697	677	0	0	1184	1912	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0
549 F	19-38		5135	3463	0	0	6647	5514	0	0	1	0	0	1	0	0	0	0	0	0	0	1	1	0	
550 M	19-38		21993	9451	0	1	14531	22031	0	1	1	0	0	0	0	0	0	0	0	1	0	1	0	0	
551 F	39-82		4350	796	0	0	1834	1019	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
552 M	19-38		2118	624	0	0	1121	690	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	
553 M	39-82		989	1031	0	0	1006	1165	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	
554 F	19-38		1847	1057	0	0	2451	1340	0	0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	
555 F	39-82	IgG/IgM positi	95001	47615	85	1	54128	25084	77	1	1	0	1	0	1	1	1	0	0	0	1	1	0	1	
556 F	19-38		4573	2083	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	1	0	0	0	0	0	0	0	1	0	0	
557 F	19-38		2262	1978	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
558 F	39-82		97111	47767	55	1	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	1	1	0	0	0	0	
559 F	19-38		1433	2001	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	0	
560 F	19-38		2034	798	0	0	4450	571	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	
561 F	39-82		19965	54292	88	1	#N/A	#N/A	#N/A	#N/A	1	1	1	1	1	0	1	0	1	1	1	1	0		
562 F	19-38		3231	383	0	0	1270	926	0	0	1	0	0	0	0	0	0	0	1	0	1	1	1	0	
563 F	39-82		2000	743	0	0	3299	1429	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
564 F	39-82	IgG/IgM positiv	19953	16924	45	1	9296	13619	0	1	1	0	1	0	0	0	0	0	1	1	1	0	0	0	
565 F	19-38		1399	716	0	0	999	286	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
566 M	19-38		2005	599	0	0	753	697	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
567 F	19-38		1002	966	0	0	834	1088	0	0	1	1	1	1	1	0	0	0	0	0	0	1	1	0	
568 F	39-82		928	964	0	0	1932	2904	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
569 F	19-38		807	476	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	0	0	0	0	0	0	0	1	0		
570 F	39-82		1585	679	0	0	1344	1151	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
571 F	39-82		32716	60426	78	1	18017	47705	85	1	1	0	0	0	0	0	0	0	1	1	0	0	0		
572 F	19-38		26371	15796	2	1	36987	27909	13	1	1	0	1	0	0	0	1	0	0	1	1	1	1	1	
573 F	39-82		1766	389	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0		
574 F	19-38		3581	1294	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	1	1	0	1	0	1	0	0		
575 F	19-38		3873	2019	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	0	0	0	0		
576 F	39-82	negative	1610	641	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	1	0	0	1	0	1	1	1	1	0		
577 F	39-82		4142	6382	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0		
578 F	19-38		6359	1173	0	0	2621	1442	0	0	1	0	1	1	0	1	0	0	1	0	0	0	0		
579 F	19-38		4681	1702	0	0	3269	2079	0	0	1	0	0	1	0	0	0	0	0	0	0	1	0		
580 F	39-82		110055	105382	85	1	68666	82251	37	1	1	1	1	0	1	1	1	0	0	1	1	0	1	1	
581 F	19-38		4931	994	0	0	1318	1656	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
582 F	39-82	negative	9310	3359	0	0	2044	1787	0	0	1	0	1	1	1	0	0	0	0	0	0	1	0		
583 F	39-82	negative	5135	1405	0	0	1242	725	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
584 M	19-38	negative	3218	829	30	1	406	312	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0		
585 M	39-82	negative	697	436	0	0	1522	973	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
586 F	39-82	negative	2998	955	0	0	1797	1330	0	0	1	0	1	1	1	1	0	0	1	1	1	0	1		
587 F	19-38		5880	884	0	0	2811	1354	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0		
588 M	39-82		6263	1840	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0		
589 M	19-38		2759	868	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	0	0	0	0	0	0	1	0	0		
590 F	39-82		3187	2017	0	0	2533	1468	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0		
591 M	19-38		571	550	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	1	0	0	0	0	0	1	1		
592 F	19-38		4025	1165	0	0	2979	805	0	0	1	1	1	1	0	1	0	1	0	1	0	0	0		
593 F	39-82		6497	804	0	0	7002	1658	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
594 F	19-38		808	662	0	0	448	787	0	0	1	1	1	1	1	1	1	0	1	0	1	1	0		
595 M	19-38		4268	665	0	0	1206	576	0	0	1	0	1	1	0	0	0	0	1	0	1	1	0		
596 M	39-82		5302	920	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	1	0	1	0	0	0	0	1	0		
597 F	19-38		3597	4041	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	1	0		
598 F	19-38		1656	663	0	0	2108	742	0	0	1	0	1	1	0	1	1	1	1	0	1	0	0		
599 F	39-82		2489	1518	0	0	763	975	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
600 F	39-82		5009	1877	0	0	4083	1612	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
601 F	39-82		7994	2217	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	1	0	1	0	0		
602 F	39-82		9486	1660	0	0	6720	1712	0	0	1	0	1	0	0	0	0	1	0	0	0	1	0		
603 F	39-82		4565	688	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	0	0	1	0		
604 F	39-82		8733	952	0	0	4934	641	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0		
605 F	19-38		2473	445	0	0	1819	531	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
606 F	19-38		38893	73484	79	1	24423	37738	7	1	1	0	1	1	0	0	0	1	0	0	1	0	1		
607 F	39-82		75217	63306	93	1	17273	61972	70	1	1	0	0	1	0	0	0	1	0	0	0	0	1		
608 M	19-38		804	728	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0		
609 F	19-38		30065	1189	0	1	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0		
610 F	19-38		2421	635	0	0	1012	651	0	0	1	0	1	0	1	0	1	0	0	0	0	1	1		
611 F	19-38		6512	4655	0	0	6789	4388	0	0	1														

624 F	19-38	2439	1775	0	0	2231	1328	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0	0
625 M	19-38	6245	1149	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
626 F	39-82	1686	2461	0	0	2219	1278	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
627 F	19-38	1595	1871	0	0	3670	1866	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
628 M	39-82	2691	448	0	0	1046	692	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0
629 M	39-82	1386	2662	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	0	0	0	1	0	0	1
630 M	39-82	3994	3302	0	0	4729	6182	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
631 M	39-82	43894	23211	93	1	11076	20487	38	1	1	1	0	0	0	0	0	1	0	0	0	0	0	1
632 F	39-82	1270	894	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	0	0	0	0	1	0	0	0
633 F	19-38	47560	141683	95	1	21984	96397	14	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
634 F	19-38	3349	590	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
635 F	39-82	1744	557	0	0	4638	557	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
636 F	19-38	23758	42708	46	1	15570	36421	2	1	1	1	1	1	1	0	0	0	0	0	0	1	1	1
637 F	19-38	1800	719	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	1	0	0	0
638 F	19-38	negative	1908	679	0	0	1193	807	0	0	1	0	1	1	0	0	0	0	0	1	0	1	0
639 F	19-38	4839	510	0	0	2042	629	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
640 F	39-82	1907	917	0	0	1809	1316	0	0	1	0	0	1	0	1	1	0	0	0	0	0	1	1
641 F	19-38	2575	1453	0	0	1219	488	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0
642 F	19-38	4288	885	0	0	2305	1401	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
643 F	39-82	3610	1014	0	0	760	413	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
644 F	19-38	2850	2025	0	0	1091	597	0	0	1	1	1	1	0	0	0	0	0	1	0	0	0	1
645 F	19-38	1107	1065	0	0	1011	1368	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0
646 F	19-38	negative	4302	820	0	0	1801	899	0	0	1	0	0	0	1	0	0	0	0	1	1	0	0
647 F	19-38	5034	3695	0	0	1546	2836	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
648 M	19-38	22061	48793	85	1	20540	55355	86	1	1	1	1	0	0	0	0	1	0	1	0	1	0	0
649 F	19-38	4190	1213	0	0	764	530	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
650 F	19-38	2864	890	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	1	0	1	0
651 F	39-82	1528	4951	0	0	710	1971	0	0	1	0	1	0	0	0	0	0	1	0	0	1	0	0
652 F	19-38	3837	575	0	0	1412	1934	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0
653 M	19-38	2127	404	0	0	839	197	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0
654 F	39-82	7549	542	0	0	2714	693	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
655 F	39-82	6660	1169	0	0	7378	1547	0	0	1	0	0	0	0	0	1	1	0	0	0	1	1	0
656 F	19-38	2874	1385	0	0	2337	1188	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
657 F	39-82	1136	455	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
658 F	39-82	1722	639	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
659 F	19-38	1369	806	0	0	733	482	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
660 F	19-38	3030	3406	0	0	4156	2058	0	0	1	0	1	0	0	0	1	1	0	0	0	0	1	0
661 F	19-38	844	578	0	0	1094	589	0	0	1	1	1	1	0	1	1	1	0	0	0	1	1	1
662 F	39-82	744	776	0	0	2359	1040	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
663 M	19-38	1182	963	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	
664 F	39-82	5474	1317	0	0	3212	2522	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
665 F	39-82	negative	3335	4270	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	1	1	1	0	0	0
666 F	39-82	2238	476	0	0	4813	735	2	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0
667 F	19-38	2259	1006	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	1	0	1	0
668 F	19-38	3744	4135	0	0	2222	1381	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
669 M	39-82	491	1682	0	0	224	278	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
670 F	39-82	1952	410	0	0	1461	546	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
671 M	19-38	3665	3978	0	0	7754	2285	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
672 F	39-82	2356	2567	0	0	1895	1888	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
673 F	39-82	4104	2343	0	0	2696	1354	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
674 F	19-38	18251	53897	82	1	12418	40410	32	1	1	0	0	1	1	0	0	0	0	0	1	1	0	0
675 F	19-38	2676	2109	0	0	4116	1686	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
676 F	19-38	1570	1636	0	0	1579	1614	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
677 F	39-82	3027	406	0	0	3182	915	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
678 F	19-38	2301	2225	0	0	2273	1197	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
679 F	19-38	6584	5913	0	0	2968	3376	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
680 F	39-82	2351	837	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
681 F	39-82	2752	4318	0	0	1146	1192	0	0	1	0	1	0	1	0	0	0	0	0	0	0	1	0
682 M	39-82	2575	1070	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	
683 M	39-82	1447	451	0	0	1247	460	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	
684 F	39-82	531	479	0	0	604	705	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
685 F	19-38	43606	139083	99	1	29197	128926	93	1	1	1	1	1	1	1	0	0	0	1	1	1	1	0
686 F	39-82	177989	234405	99	1	78196	104388	0	1	1	1	1	1	1	1	0	1	0	0	1	1	0	1
687 F	19-38	2316	601	0	0	1909	876	0	0	1	0	1	0	0	0	0	1	0	1	0	1	0	0
688 F	39-82	1731	831	0	0	1331	642	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
689 M	39-82	2131	1075	0	0	1476	1545	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
690 F	39-82	9179	2207	0	0	3028	1339	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
691 F	19-38	28929	7501	0	1	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	0
692 F	19-38	6183	1452	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	1	0	0	0	0	0	0	0	0	0
693 F	19-38	2208	858	0	0	907	979	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1
694 F	19-38	5354	1761	0	0	2625	2503	0	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0
695 F	19-38	7518	528	0	0	6097	478	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
696 M	19-38	4079	412																				



778 F	39-82	1245	1355	0	0	2580	1397	0	0	1	1	1	0	0	0	0	0	1	0	1	0	0
779 F	19-38	6421	5251	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
780 F	19-38	1283	2236	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
781 F	19-38	5318	559	0	0	2130	956	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
782 M	19-38	7139	989	0	0	2847	957	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
783 F	19-38	2034	509	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	1	1	0
784 F	39-82	5614	1001	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	0	0	0	0	1	0	1	1	0
785 F	39-82	1342	3084	0	0	1155	3131	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
786 F	19-38	841	422	0	0	849	547	0	0	1	0	1	1	0	0	0	0	0	0	0	1	0
787 F	19-38	3337	3654	0	0	736	1159	0	0	1	0	1	0	0	0	0	0	0	0	0	1	1
788 F	39-82	2420	425	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	1	1	1	0	0	0	1	1	0
789 F	39-82	104219	69779	81	1	16760	47551	65	1	1	1	0	1	0	0	0	0	0	0	1	0	0
790 M	39-82	2592	985	0	0	2401	1534	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
791 F	39-82	9055	3250	0	0	4250	4938	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
792 M	39-82	15477	8309	0	1	14376	8602	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
793 F	19-38	1568	3743	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	1	0
794 F	39-82	2016	1083	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	1	0	1	0	1	0
795 M	39-82	1022	7764	0	0	833	5697	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
796 F	19-38	2319	3771	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
797 M	39-82	5086	618	0	0	1300	330	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
798 F	39-82	3233	2157	0	0	2265	1908	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
799 F	39-82	2011	2082	0	0	2750	1967	18	1	1	0	1	1	0	0	0	1	0	1	0	1	0
800 M	19-38	2360	2854	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
801 M	39-82	6623	6226	0	0	1764	1426	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
802 F	39-82	445	688	0	0	671	736	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
803 F	39-82	1540	605	0	0	1180	567	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
804 M	19-38	3568	862	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
805 F	19-38	43029	48682	70	1	21182	112738	97	1	1	1	1	1	1	1	0	0	0	0	0	0	0
806 M	19-38	1598	3238	0	0	1491	3310	0	0	1	1	1	1	0	0	1	0	1	0	1	0	0
807 M	39-82	1599	50	0	0	1079	679	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
808 F	39-82	5565	67	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	0	0	1	0	0	0	0
809 M	19-38	2422	757	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	1	1	1	0	0	0	1	1	0
810 M	19-38	72380	117519	97	1	18810	66318	97	1	1	1	1	1	1	0	0	1	1	1	1	1	0
811 F	39-82	993	38	0	0	1824	2523	0	0	1	1	1	1	0	0	0	1	1	1	0	1	1
812 F	39-82	1390	82	0	0	1470	519	0	0	1	0	1	0	0	0	0	0	0	1	1	0	0
813 F	19-38	790	23	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	1	0	1	0	1	0
814 F	19-38	1705	97	0	0	1092	1121	0	0	1	1	1	1	0	0	1	1	0	0	1	0	0
815 F	19-38	7183	799	0	0	8604	937	0	0	1	0	1	0	0	0	0	1	1	0	1	0	0
816 F	39-82	12479	1105	0	1	14397	13885	0	1	1	0	1	0	0	0	0	1	0	0	0	1	0
817 F	39-82	4031	1553	0	0	1830	953	0	0	1	1	1	1	0	0	0	1	0	0	0	1	0
818 F	39-82	1816	664	0	0	310	511	0	0	1	0	1	1	0	0	1	1	0	1	0	1	0
819 F	39-82	3666	480	0	0	2396	567	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0
820 F	19-38	1059	2794	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	1	0	0	1	0	0	0
821 F	39-82	743	1414	0	0	999	1008	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
822 F	19-38	2489	1178	0	0	1757	742	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0
823 F	39-82	9837	1190	0	0	5862	1368	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
824 F	19-38	1195	494	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	1	0	0	1	1	0	0	1	0
825 F	19-38	1111	825	0	0	1478	1089	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
826 F	19-38	2766	1196	0	0	1181	527	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
827 F	39-82	4480	1205	0	0	3156	743	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
828 F	19-38	648	2261	0	0	2281	4345	0	0	1	1	1	1	0	0	0	1	0	1	0	1	0
829 F	19-38	4415	988	0	0	4897	1295	0	0	1	0	1	1	0	1	1	1	1	0	1	0	0
830 F	39-82	1146	454	0	0	1054	437	0	0	1	0	0	0	0	0	1	1	0	0	0	0	1
831 F	19-38	1640	1864	0	0	4729	5121	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
832 M	19-38	107478	25830	84	1	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	1	1	1	1	0	0
833 M	19-38	3267	858	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	1	0	0	1	0
834 F	19-38	2629	1139	0	0	3519	1467	0	0	1	1	1	1	1	1	1	1	1	1	1	1	0
835 F	19-38	5182	3823	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
836 M	39-82	5647	5193	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
837 F	19-38	7014	3621	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0
838 M	19-38	205635	182327	99	1	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	1	0	0	1	0
839 M	39-82	3845	996	0	0	2221	2446	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
840 F	39-82	2432	1688	0	0	2113	1992	0	0	1	0	1	1	0	0	0	1	0	1	0	0	0
841 F	19-38	3725	1049	0	0	2315	725	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0
842 F	19-38	10206	801	0	0	4334	2873	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
843 M	39-82	158428	56132	89	1	21856	33847	60	1	1	1	0	0	0	0	0	0	0	0	0	1	0
844 F	39-82	1386	1017	0	0	891	867	4	1	1	0	1	0	1	0	0	0	0	0	0	0	0
845 F	39-82	2272	689	0	0	1518	925	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
846 M	39-82	4406	6985	0	0	2705	6308	7	1	0	0	0	0	0	0	0	0	0	0	0	0	0
847 F	39-82	1873	794	0	0	1075	800	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0
848 F	19-38	30250	34324	77	1	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	1	1	1	1	1	0	0	0
849 F	19-38	6576	3138	0	0	870	490	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
850 F	19-38	3658	1969	0	0	2862	1442	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0
851 M	19-38	9516	2476	0	0	7796	2345	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
852 F	39-82	2857	462	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	1	0	0	1	0	1	0	1	0	



















1562 M	19-38	1918	1001	0	0	666	289	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
1563 F	39-82	1825	1982	0	0	779	1031	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0
1564 M	39-82	2548	3177	0	0	684	1313	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0
1565 M	39-82	8887	1361	0	0	5284	660	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	1	0	0
1566 F	39-82	1231	1206	0	0	620	698	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1567 M	39-82	4850	1063	0	0	1976	1227	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
1568 M	19-38	1126	1213	0	0	195	681	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	1	0
1569 F	39-82	2430	1574	0	0	1113	287	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1570 F	19-38	1103	1855	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
1571 F	39-82	1710	826	0	0	1728	424	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1572 F	19-38	892	1470	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0
1573 F	39-82	1498	1270	0	0	1096	616	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
1574 F	19-38	1201	3922	0	0	427	2181	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1575 F	39-82	4003	1857	0	0	3500	1154	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1576 F	39-82	3555	1282	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
1577 F	39-82	2305	1883	0	0	1441	1013	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1578 F	39-82	1345	1982	0	0	679	996	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0
1579 H	19-38	1577	1647	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1580 F	19-38	1623	1384	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1581 F	39-82	3259	1764	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1582 H	19-38	4502	1695	0	0	2361	2352	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1583 F	19-38	4260	2713	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	1	1	0
1584 F	39-82	1197	720	0	0	536	211	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1585 F	19-38	1676	1967	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1586 F	19-38	6673	2388	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0
1587 F	19-38	3120	1553	0	0	4170	943	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1588 F	19-38	2337	10538	0	1	2357	1020	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1589 F	39-82	4932	832	0	0	3548	176	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1590 F	39-82	1467	3128	0	0	836	2189	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0	1	0
1591 M	19-38	1437	4198	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1592 F	39-82	1180	1398	0	0	960	1560	0	0	1	0	1	1	0	0	1	1	1	0	1	0	1	0	1	0
1593 F	19-38	9858	865	0	0	9041	427	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1594 F	39-82	2070	1419	0	0	1154	437	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1595 M	39-82	1197	1446	0	0	471	751	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1596 F	19-38	2068	1685	0	0	4489	973	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0
1597 F	19-38	2876	6306	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1598 M	39-82	212526	324261	96	1	168511	119701	87	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
1599 F	19-38	3086	877	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1600 F	39-82	2187	859	0	0	1432	1105	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0
1601 F	39-82	1591	1698	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1602 F	19-38	1021	1228	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	1	0	0	0	0	0	0	1	0	0	
1603 F	19-38	2940	2267	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	1	0	0	0	0	0	1	0	
1604 H	39-82	1235	810	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	
1605 F	19-38	4397	2766	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1606 F	19-38	2503	1752	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	1	1	1	0	0	0	0	0	1	0	
1607 F	19-38	973	1731	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1608 F	19-38	3409	1686	0	0	2375	853	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
1609 F	39-82	1540	1790	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1610 F	39-82	7652	2020	0	0	6396	997	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0
1611 F	19-38	2570	1411	0	0	1324	551	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1612 H	39-82	2384	1545	0	0	1741	1394	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
1613 H	39-82	18869	40418	56	1	12459	36352	21	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0
1614 F	19-38	2030	3004	0	0	1664	2885	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
1615 F	19-38	1240	834	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1616 F	19-38	997	1142	0	0	#N/A	#N/A	#N/A	#N/A	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	
1617 F	19-38	9432	668	0	0	11396	800	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1618 F	19-38	1231	2946	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	
1619 F	19-38	2141	1870	0	0	1303	824	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1620 M	39-82	1487	3304	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	
1621 F	19-38	2583	1395	0	0	2118	2975	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0
1622 F	19-38	1964	830	0	0	1683	804	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
1623 F	19-38	1772	1600	0	0	1274	1058	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1624 F	39-82	735	528	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	1	1	1	1	1	0	0	0	0	1	0	0
1625 M	19-38	2044	1362	0	0	2456	692	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1626 F	19-38	1377	828	0	0	692	411	0	0	1	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0
1627 M	39-82	2488	3136	0	0	1605	2393	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1628 F	19-38	1523	1396	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1629 F	39-82	1631	2638	0	0	769	978	0	0</td																

1639 F	19-38		4103	1121	0	0	2485	561	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
1640 F	19-38	negative	1923	1178	0	0	855	480	0	0	1	0	1	1	0	0	0	1	0	0	1	1	0	0
1641 M	39-82		1270	1993	0	0	957	871	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1642 F	39-82		1602	1130	0	0	627	548	0	0	1	0	1	0	1	1	1	1	0	0	0	1	1	0
1643 F	19-38		4371	1358	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1644 H	19-38		2543	2233	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1645 H	19-38		1449	1147	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1646 H	39-82		1676	1250	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	0
1647 F	19-38		1775	1277	0	0	1186	902	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1648 M	19-38		1109	1030	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	1	0	0	0	0	0	0	0
1649 M	19-38		1451	3003	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	1	0	0
1650 F	19-38		4330	1585	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1651 M	19-38		5918	1305	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	1	0	0	0	1	0	0
1652 M	19-38		1759	2654	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1653 F	39-82		1015	830	0	0	329	215	0	0	1	1	1	1	0	0	0	1	0	0	0	1	0	0
1654 F	19-38		3159	1417	0	0	2968	1013	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1655 F	39-82		2355	1623	0	0	1558	786	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0
1656 F	39-82		2164	1490	0	0	1244	485	0	0	1	1	0	1	0	0	0	0	0	0	0	1	0	0
1657 M	19-38		2140	3886	0	0	697	1402	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1658 M	19-38		1704	1588	0	0	672	545	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1659 M	19-38		6269	1277	0	0	2887	568	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1660 F	19-38		1698	1273	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1661 F	19-38		2602	3331	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	0
1662 F	19-38		16597	622	0	1	11847	1402	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1663 F	39-82		8977	2865	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	1	0	0
1664 F	19-38		1197	2543	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	1	0	0	1	0	0
1665 F	19-38		1429	873	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	0	0	0	0	0	0	0
1666 F	19-38		3348	1098	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1667 F	19-38		1835	2152	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	1	0
1668 F	39-82		1888	1658	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	1	0	0	0	0	1	0	0
1669 F	39-82		637	7531	0	0	528	3346	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1670 F	19-38		1702	1349	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1671 M	19-38		2193	1872	0	0	1451	1485	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1672 M	19-38		1270	1677	0	0	977	934	0	0	1	0	1	0	0	0	0	1	0	0	0	0	1	0
1673 F	39-82		1577	703	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	0	0	0	0	0	0	0	0	1	0	0
1674 F	39-82		3659	744	0	0	4002	1029	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1675 F	39-82		1144	759	0	0	1005	799	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0
1676 F	39-82		2099358	207754	98	1	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	1	1	0	0	0	1	1	1	0
1677 F	19-38		3204	1022	0	0	#N/A	#N/A	#N/A	#N/A	1	1	0	0	0	0	0	0	0	0	0	0	1	0
1678 H	39-82		3185	2338	0	0	1445	632	0	0	1	0	1	1	1	1	0	1	0	1	0	1	1	0
1679 F	39-82		1097	674	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1680 F	19-38		2952	1460	0	0	2427	1078	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1681 M	19-38		3179	1532	0	0	#N/A	#N/A	#N/A	#N/A	1	0	0	1	0	0	0	1	1	0	0	0	1	0
1682 F	19-38		2322	2398	0	0	1640	1065	0	0	1	0	1	1	0	0	0	0	1	0	0	1	0	0
1683 F	19-38		1286	2805	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1684 H	19-38		2742	5027	0	0	1557	343	0	0	1	1	0	1	1	1	1	1	1	0	1	0	1	0
1685 H	39-82		1246	879	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	0	0	0	0	0	0	0	0	0
1686 H	39-82		1266	4286	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	1	0	0	0	0	0	0	0	0	0	0
1687 F	19-38		806	818	0	0	761	1226	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1688 F	39-82		1230	3329	0	0	2709	1460	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0
1689 F	39-82		5850	901	0	0	5558	1116	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1690 F	19-38		1599	1314	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1691 F	19-38		2969	6473	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	1	0	0
1692 M	39-82		2005	1150	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	1	0	0	1	0	0
1693 F	19-38		5495	2166	0	0	3351	585	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1694 H	39-82		2025	991	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	1	0	0	1	0	0	1	0	0
1695 F	39-82		1639	6345	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	0	0	0
1696 H	19-38		2344	2037	0	0	#N/A	#N/A	#N/A	#N/A	1	1	1	0	0	0	0	1	0	0	0	0	0	0
1697 F	19-38		1896	6350	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	1	0	1	0	1	0	0	1	1	0	0
1698 F	39-82		2643	646	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1699 F	39-82		1660	1118	0	0	1297	937	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1700 F	19-38		3815	1248	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	1	0	0	0	0	0	0	1	0	0
1701 F	39-82		1977	690	0	0	1042	720	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1702 F	39-82		2144	1114	0	0	929	823	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1703 M	39-82		4548	1244	0	0	3349	891	0	0	1	1	0	1	0	0	0	0	1	0	0	0	0	0
1704 F	39-82		1091	1021	0	0	812	692	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1705 F	19-38		3436	2515	5	1	2169	881	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1706 F	39-82		2378	611	0	0	1544	4277	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1707 F	39-82		9131	408	0	0	9074	763	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1708 F	19-38		3032	3086	0	0	1520	746	0	0	1	0	0	1	0	1	0	0	0	0	0	1	0	0
1709 F	19-38		1561	949	0	0	#N/A</td																	





1878 F	19-38		1806	577	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1879 F	39-82		1064	348	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1880 M	39-82		895	429	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1881 M	19-38		923	306	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1882 M	39-82		860	392	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1883 F	39-82		756	1102	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1884 F	39-82		1154	413	0	0	#N/A	#N/A	#N/A	#N/A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1885 F	19-38		1195	1338	0	0	#N/A	#N/A	#N/A	#N/A	1	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0

0